APRE ▲ +8.1% - Aprea Therapeutics, Inc. $APRE - Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium Aprea Therapeutics rose 8.1% today following an announcement that the company will present updated interim Phase 1 data for its WEE1 inhibitor APR-1051 at the 38th EORTC-NCI-AACR Symposium. The presentation of new clinical data at a major oncology conference typically draws investor interest as it provides an opportunity to showcase drug development progress to the medical and investment communities. 22-SEP-2026 08:30 AM ET